Balyasny Asset Management
KALV

Balyasny Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Balyasny Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Buy
+11,098
New +$179K ﹤0.01% 2659
2024
Q4 		– Sell
-26,968
Closed -$312K – 3009
2024
Q3 		$312K Buy
+26,968
New +$339K ﹤0.01% 2443
2024
Q1 		– Sell
-11,905
Closed -$146K – 2874
2023
Q4 		$146K Buy
11,905
+1,235
+12% +$11.2K ﹤0.01% 2352
2023
Q3 		$103K Buy
+10,670
New +$109K ﹤0.01% 2126

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management's KALV Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 11,098 shares worth $223K. The stake represents ﹤0.01% of the portfolio and ranks #2659 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in KALV as recently as Q3 2024.

Balyasny Asset Management first reported a position in KALV in Q3 2023 and has held it in 4 quarters since. The position peaked at $312K in Q3 2024. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • Balyasny Asset Management held 11,098 shares of KalVista Pharmaceuticals worth $223K as of Q1 2026.
  • KalVista Pharmaceuticals was a new Balyasny Asset Management position in Q1 2026.
  • KalVista Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2659 holding.
  • Balyasny Asset Management first reported a position in KalVista Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
  • Balyasny Asset Management's KalVista Pharmaceuticals position peaked at $312K in Q3 2024.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.